Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia
Por:
Fuster JL, Bautista F, González B, Fernández JM, Rives-Solà S and Dapena JL
Publicada:
1 sep 2021
Ahead of Print:
1 mar 2021
Resumen:
Filiaciones:
Fuster JL:
Pediatric Oncology and Hematology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB), Ctra. Madrid-Cartagena s/n, El Palmar, 30120, Murcia, Spain.
Bautista F:
Pediatric Oncology, Hematology and Stem Cell Transplantation Department, Hospital Niño Jesús, Madrid, Spain
González B:
Pediatric Oncology and Hematology Department, Hospital Universitario La Paz, Madrid, Spain
Fernández JM:
Pediatric Oncology and Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Rives-Solà S:
Pediatric Hematology and Oncology Department, Hospital San Joan de Déu, Institut de Recerca San Joan de Déu, Barcelona, Spain
Dapena JL:
Pediatric Hematology and Oncology Department, Hospital San Joan de Déu, Institut de Recerca San Joan de Déu, Barcelona, Spain
|